Bajaj Healthcare Reports Q1 FY27 Results: Revenue Up 11.3%, EBITDA Grows 16.4% YoY

Bajaj Healthcare Reports Q1 FY27 Results: Revenue Up 11.3%, EBITDA Grows 16.4% YoY​

Bajaj Healthcare Limited, a leading manufacturer of APIs, Intermediates, and Formulations, announced its unaudited financial results for the quarter ended June 30, 2026. The company reported healthy growth across key financial parameters in Q1 FY27.

Key Financial Highlights​

The company recorded Revenue from operations at Rs. 165.6 Crore, marking an increase of 11.3% year-over-year (YoY) and 8.2% sequentially. Gross profit stood at Rs. 80.4 Crore, rising 16.2% YoY. The gross margin expanded to 48.3%, up from 46.2% in Q1 FY26.

EBITDA reached Rs. 29.6 Crore, which is a 16.4% increase compared to the previous year. The EBITDA margin improved to 17.8%, an improvement from 17.1% in Q1 FY26. Profit after tax (PAT) was reported at Rs. 13.7 Crore, reflecting a 15.8% YoY rise, with a PAT margin of 8.3%.

Business Segment Performance​

The API domestic segment demonstrated robust growth, generating sales of Rs. 92.3 Crore for the quarter. This represented a approximately 27% increase compared to Rs. 72.6 Crore in Q1 FY26, driven by strong volume growth across key products.

API export sales amounted to Rs. 50.1 Crore. This figure was slightly lower than the Rs. 52.2 Crore recorded in Q1 FY26, a trend attributed to temporary disruptions arising from the geopolitical situation in West Asia.

In terms of Formulations, revenue was Rs. 23.3 Crore for the quarter, compared to Rs. 24.1 Crore in Q1 FY26, indicating a temporary moderation period. The company expects this segment's performance to normalize as FY27 progresses.

Operational and Regulatory Updates​

Bajaj Healthcare secured a significant regulatory milestone by becoming the first company in India to receive the SEC recommendation for the manufacture and marketing of Cenobamate Tablets. This medication is designed for treating partial-onset seizures in adults, representing a key step toward commercialization.

Furthermore, during the quarter, the Company filed two CEP applications, bringing the cumulative CEP filings to twelve. Eight of these have been approved, with four currently under review, which enhances the company's positioning in the regulated European Union (EU) and United Kingdom (UK) markets.

Management Commentary​

Anil Jain, Managing Director, commented on the results, noting that FY27 commenced on a positive note characterized by healthy growth across all key financial metrics. He highlighted the gross margin expansion to 48.3% from 46.2%, and the improvement in EBITDA margin to 17.8%.

Mr. Jain stated that while the formulations segment saw a marginal decline, the business mix is anticipated to gradually normalize as FY27 progresses. He added that the state-of-the-art R&D Centre at Savli is now operational, significantly boosting product development capabilities. The company remains committed to delivering sustainable growth and enhancing long-term value for shareholders.

Financial Snapshot: Q1 FY27 Performance​

The detailed financial performance across segments and key metrics is provided in the table below:


For a comprehensive view, the full financial details for Q1 FY27 are as follows:

BAJAJHCARE Stock Price Movement​

Bajaj Healthcare Limited shares finished today in strong gains, climbing 4.56% to settle at ₹386.55. The stock saw a total traded volume of 1.01 million shares during the session.